- Home - Annexon Biosciences
Dr Barres co-founded Annexon Biosciences and was a Professor and Chair of Neurobiology at Stanford University School of Medicine He received his BS from Massachusetts Institute of Technology, his MD from Dartmouth Medical School and his PhD at Harvard Medical School in the laboratory of David Corey
- Annexon Biosciences - LinkedIn
Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative,
- Annexon to Present on the Neuroprotective Effects of ANX007
Annexon Biosciences (Nasdaq: ANNX) is developing therapeutics that stop classical complement-driven neurodegeneration as first-in-kind treatments for millions of people living with serious
- Annexon Biosciences 2025 Company Profile: Stock Performance . . .
Information on stock, financials, earnings, subsidiaries, investors, and executives for Annexon Biosciences Use the PitchBook Platform to explore the full profile
- Pipeline - Annexon Biosciences
Annexon is pioneering a class of new complement medicines for patients with classical complement-mediated disorders of the body, brain and eye We are conducting ongoing clinical trials in multiple serious autoimmune, neurodegenerative and ophthalmic diseases
- Annexon Biosciences Company Profile - Office Locations . . .
Annexon Biosciences is a clinical-stage biopharmaceutical company that develops complementary medicines for patients with complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye
- Annexon | Redwood City, CA, USA Startup
Annexon is discovering and developing novel disease modifying drugs for neurodegenerative disorders that represent unmet medical needs We are building an antibody platform that targets various components of the complement system
- Annexon, Inc. - BioSpace
With Phase III trial results looming in the second quarter of 2024, Annexon Biosciences aims to transform treatment for Guillain-Barre syndrome with its investigational antibody, ANX005 The candidate is also being trialed in Huntington disease and ALS
|